Meeting
2018 Genitourinary Cancers Symposium
Safety and efficacy of abiraterone acetate (AA) in patients aged 75 or more with metastatic castration-resistant prostate cancer (mCRPC) in both pre-chemotherapy or post-chemotherapy settings: Real-life experience from thirteen Italian centers.
Authors
Zuzana Sirotova
Oncology and Onco-hematology, Regional Hospital Parini, Aosta, Italy
Zuzana Sirotova , Giulia Courthod , Alfredo Tartarone , Orazio Caffo , Francesca Maines , Maurizio Bertuccelli , Franco Morelli , Gianmauro Numico , Pamela Guglielmini , Giuseppe Fornarini , Veronica Prati , Erica Palesandro , Cinzia Ortega , Alessandra Mosca , Stefania Miraglia , Valentina Perrone , Elena Fea , Giacomo Allegrini , Alessandro Mozzicafreddo , Marina Schena
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 209)
DOI
10.1200/JCO.2018.36.6_suppl.209
Abstract #
209
Poster Bd #
K7
Abstract Disclosures
Similar Posters
Poster
2015 Genitourinary Cancers Symposium
Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Alice Clement-Zhao
Poster
2023 ASCO Genitourinary Cancers Symposium
Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study.
First Author: Vincenzo Gennusa
Poster
2022 ASCO Annual Meeting
PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Shahneen Sandhu
Poster
2020 ASCO Virtual Scientific Program
Efficacy and safety in older patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone (ABI) or enzalutamide (ENZ) in the CARD study.
First Author: Cora N. Sternberg